PROTAGONIST THERAPEUTICS INC (PTGX)
Health Care · NASDAQ
A clinical-stage biotech developing targeted oral and injectable peptide therapeutics across inflammation, hematology, and obesity with validated partnerships including Janssen and Takeda.
What PROTAGONIST THERAPEUTICS INC does
Protagonist Therapeutics is an integrated discovery and development company focused on creating novel peptide and small-molecule medicines across inflammation & immunology, hematology, and metabolic diseases. The company has advanced three lead programs with major pharma partnerships: Icotyde (IL-23 receptor antagonist for psoriasis) licensed to Janssen, rusfertide (hepcidin mimetic for polycythemia vera) co-developed with Takeda, and PN-881 (IL-17 antagonist for skin diseases) in Phase 1. The company is also building a portfolio of obesity programs including triple agonists (PN-477) and dual GLP-1/GIP agonists (PN-458), supported by $646 million in cash and marketable securities as of fiscal year-end 2025.
Themes: ["IL-23 inhibition / psoriasis","IL-17 inhibition / immune-mediated skin diseases","GLP-1 / GIP agonists / obesity","Hepcidin mimetics / polycythemia vera","Oral peptide therapeutics","Rare blood disorders / hematology","Atopic dermatitis / asthma"]
Fundamentals
- Price$137.64 as of 2026-07-09 close
- Market cap$8.8B as of 2026-07-10
- 1-year return+163.2% as of 2026-07-09 close
- Net margin-154.9% as of 2026-07-10
- ROE-17.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-64.4% as of 2026-07-10
- Beta1.79 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Amgen (AMGN) - IL-23 and IL-17 inhibitors for psoriasis
- Eli Lilly (LLY) - GLP-1/GIP agonists for obesity
- Novo Nordisk (NVO) - GLP-1 agonists for obesity and diabetes
- AstraZeneca (AZN) - obesity therapeutic programs
- Roche (RHHBY) - atopic dermatitis and autoimmune programs
- Abbvie (ABBV) - immunology and dermatology portfolio
- Vertex Pharmaceuticals (VERX) - rare disease focus
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.